Olajumoke Evangelina Owokotomo<sup>1</sup> Ziv Shkedy<sup>1</sup> Adetayo Kasim<sup>2</sup>


40th Annual Conference of the International Society for Clinical Biostatistics on July, 17th 2019

<sup>&</sup>lt;sup>1</sup>Interversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat) Center for Statistics (CenStat), Hasselt University, Diepenbeek, Belgium.

<sup>&</sup>lt;sup>2</sup>Wolfson Research Institute, Durham University, Durham, United Kingdom.

Background

### Surrogacy measure and evaluation




- Different evaluation approach in the literature
- Goal : A new measure of surrogacy


Background

### What is new?

- An easy and simple measure.
- Applied to any type of endpoints combination.
- Model uncertainty is taken into account.
- Based on a probability measure which gives the importance of an endpoint as a biomarker.
- It is related to other measures for surrogacy Buyse and Molenberghs, 1998, Alonso and Molenberghs, 2001.

### • A Bayesian Variable Selection approach.





$$\begin{pmatrix} X \\ Y \end{pmatrix} \sim \mathcal{N} \begin{pmatrix} \mu_X + \alpha Z \\ \mu_Y + \beta Z + \gamma X \end{pmatrix}, \quad \Sigma \quad \end{pmatrix} \qquad \qquad \begin{pmatrix} X \\ Y \end{pmatrix} \sim \mathcal{N} \begin{pmatrix} \mu_X + \theta_1 \phi_1 Z \\ \mu_Y + \theta_2 \phi_2 Z + \theta_3 \phi_3 X \end{pmatrix}, \quad \Sigma \quad \end{pmatrix}$$

$$\alpha = \phi_1^* \theta_1$$
,  $\beta = \phi_2^* \theta_2$ ,  $\gamma = \phi_3^* \theta_3$ .

$$\phi_i \sim B(\pi_i)$$
 and  $\pi_i \sim U(0,1)$ 


$$\phi_i = \begin{cases} 1, & \theta_i \text{ is included in the model,} \\ 0, & \theta_i \text{ is not included in the model.} \end{cases}$$

$$heta_1, heta_2, heta_3 \sim \mathcal{N}(0, 0.00001) \ \Sigma^{-1} \sim \textit{dwish}(\textit{W}, \textit{df})$$

$$W = \begin{pmatrix} 1 & 0 \\ 0 & 1 \end{pmatrix}, \qquad df = 2$$

$$\phi = \{\phi_1, \phi_2, \phi_3\}$$

- The configuration of  $\phi$  define uniquely all possible models;
- Example: If  $\phi = \{1, 0, 1\}$  then;




• Z influences Y indirectly via X.

### Inclusion probability

- Inclusion probability as measure of surrogacy.
- $\pi_i = P(\phi_i = 1 | \text{data, model paramters}).$
- Example:

```
P(\phi_3 = 1 | \text{data, model paramters}) =
P(X \text{ is included in the model}).
```


# The transPAT study




- Measurements:
  - Microbiome Data
  - 2 Immunological Data

 Research question: Is the PAT altered Microbiota sufficient to alter Intestinal Immunity?

## Immunological data



# Microbiome data(1)



# Microbiome data(2)

 $x_{1,15}$  $x_{2,1}$ 355 OTUs II ٤  $x_{355,9}$   $x_{355,10}$  . . . **PAT altered Group Control Group** 

 Similar in structure to other omics data: gene expression data, metabolic data...




#### Data structure

- Repeated measurements at 4 time points
- 355 OTU's = 30 families
- A subject : Mouse
- Observation unit =  $\{Z_i, Y_i, X_{ij}\}$


$$Y = \begin{bmatrix} Y_1 \\ Y_2 \\ \vdots \\ Y_{15} \end{bmatrix}, X = \begin{bmatrix} X_{1,1} & X_{1,2} & \cdots & X_{1,15} \\ X_{2,1} & X_{2,2} & \cdots & X_{2,15} \\ \vdots & \vdots & \vdots & \vdots \\ X_{30,1} & X_{30,2} & \cdots & X_{30,15} \end{bmatrix}, Z = \begin{bmatrix} Z_1 \\ Z_2 \\ \vdots \\ Z_{15} \end{bmatrix}$$

- Richness: Number of nonzero OTUs for a subject
- Family Level richness: Richness belonging to a particular family

#### Family richness over time



Results •0000



```
X_i \sim Pois(\lambda_i)
log(\lambda_i) = \mu_x + \phi_1 * \theta_1 Z_i
                                                                                                  \alpha = \phi_1^* \theta_1; \phi_1 = 1 then \alpha = \theta_1
                                                                                                  \beta = \phi_2^* \theta_2; \phi_2 = 1 then \beta = \theta_2
Y_i \sim N(\mu_i, \tau)
                                                                                                  \gamma = \phi_3^* \theta_3: \phi_3 = 1 then \gamma = \theta_3
\mu_i = \mu_V + \frac{\phi_2}{2} \theta_2 Z_i + \frac{\phi_3}{2} \theta_3 X_i
```

#### Priors specification

```
\mu_{\mathsf{x}}, \mu_{\mathsf{y}}, \alpha, \beta, \gamma \sim \mathsf{N}(0, 0.00001)
\tau \sim Gamma(0.00001, 0.00001)
                              \phi_i \sim B(\pi_i) and \pi_i \sim U(0,1)
```

### Design matrix for the indicators

• Matrix of indicator for the 8 models:

$$\Phi = egin{pmatrix} \phi_1 & \phi_2 & \phi_3 \ 0 & 0 & 0 \ 1 & 0 & 0 \ 0 & 1 & 0 \ 0 & 0 & 1 \ 1 & 0 & 1 \ 1 & 1 & 0 \ 0 & 1 & 1 \ 1 & 1 & 1 \end{pmatrix}$$

• Unique identification of a model

$$C = \{1, 2, 4\}$$
  
 $T_r = 1 + \Phi C$ 

## Models' posterior probability


Transformation rule for each model

$$T_r = \begin{cases} 1, & \text{for } \phi = (\phi_1 = 0, & \phi_2 = 0, & \phi_3 = 0), & \text{model } m_1 \\ 2, & \text{for } \phi = (\phi_1 = 1, & \phi_2 = 0, & \phi_3 = 0), & \text{model } m_2 \\ 3, & \text{for } \phi = (\phi_1 = 0, & \phi_2 = 1, & \phi_3 = 0), & \text{model } m_3 \\ 5, & \text{for } \phi = (\phi_1 = 0, & \phi_2 = 0, & \phi_3 = 1), & \text{model } m_4 \\ 6, & \text{for } \phi = (\phi_1 = 1, & \phi_2 = 0, & \phi_3 = 1), & \text{model } m_5 \\ 4, & \text{for } \phi = (\phi_1 = 1, & \phi_2 = 1, & \phi_3 = 0), & \text{model } m_6 \\ 7, & \text{for } \phi = (\phi_1 = 0, & \phi_2 = 1, & \phi_3 = 1), & \text{model } m_7 \\ 8, & \text{for } \phi = (\phi_1 = 1, & \phi_2 = 1, & \phi_3 = 1), & \text{model } m_8 \end{cases}$$

Posterior probability of transformation

$$p(m_4|\phi, \text{data}) = p(T_r = 5|\phi, \text{data})$$


# Inclusion probability (per day)





•  $P(\phi_3 = 1|data)$  develops over time

### What is the probability for X to be a biomarker at day 20?



$$\begin{split} P(\phi_1 = 1|\textit{data}) &= P(m_2) + P(m_5) + P(m_6) + P(m_8) = 0.9996 \\ P(\phi_2 = 1|\textit{data}) &= P(m_3) + P(m_6) + P(m_7) + P(m_8) = 0.5007 \\ &\qquad \qquad \underbrace{\text{Probability that X is a biomarker}}_{P(\phi_3 = 1|\textit{data})} &= P(m_4) + P(m_5) + P(m_7) + P(m_8) = 0.96045 \end{split}$$

### Conclusion and Further Research

#### Conclusion

- Bayesian extension of the JM for all type of distribution
- The probability of inclusion as a measure of surrogacy
- Richness as a biomarker was seen to be highly related to the IgA over time

#### Further research

- To take into account the longitudinal information
- Incorporate other features
- Testing the method on a better dataset (small sample and few active features)
- Establish a connection between our method and the information criteria approach through simulation.